GlassScriptPhysician profile
Daniel H Ober
NPI 1013902261
$1,828.87
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $35.78 · 2023: $444 · 2024: $858 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $470.57 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $275.06 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $175.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $134.52 | 2023-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $132.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $120.33 | 2023-2024 | |
| Pfizer INC. | $82.39 | 2023-2024 | |
| Abbvie INC. | $73.77 | 2024 | |
| Glaxosmithkline, LLC. | $50.71 | 2023 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $43.69 | 2024 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Ge Healthcare | $35.78 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.64 | 2025 | Givlaari |
| Sumitomo Pharma America, INC. | $26.41 | 2024 | Myfembree |
| Regeneron Healthcare Solutions, INC. | $24.62 | 2024 | Evkeeza |
| Exeltis, USA INC. | $24.46 | 2024 | Slynd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22.30 | 2021 | |
| Medtronic, INC. | $22.22 | 2024 | Truclear |
| Lilly USA, LLC | $20.50 | 2024 | Jardiance, Zepbound |
| Amgen INC. | $17.58 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.51 | 2024 | Voquezna |
| Avion Pharmaceuticals | $16.05 | 2023 | Balcoltra |
| Viiv Healthcare Company | $14.61 | 2025 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.